Literature DB >> 28329350

Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa.

Jose M Munita1,2,3, Samuel L Aitken1,4, William R Miller1,2, Federico Perez5, Rossana Rosa6,7, Luis A Shimose6,7, Paola N Lichtenberger7, Lilian M Abbo6,7, Rupali Jain8, Masayuki Nigo2, Audrey Wanger9, Rafael Araos3, Truc T Tran1,2, Javier Adachi10, Robert Rakita11, Samuel Shelburne10, Robert A Bonomo5, Cesar A Arias1,2,12.   

Abstract

A multicenter, retrospective study of patients infected with carbapenem-resistant Pseudomonas aeruginosa who were treated with ceftolozane/tazobactam was performed. Among 35 patients, pneumonia was the most common indication and treatment was successful in 26 (74%). Treatment failure was observed in all cases where isolates demonstrated ceftolozane-tazobactam minimum inhibitory concentrations ≥8 μg/mL.
© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  P. aeruginosa; carbapenem resistant; ceftolozane; multidrug resistant

Mesh：

Substances：

Year:  2017        PMID： 28329350      PMCID： PMC5850333          DOI： 10.1093/cid/cix014

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  13 in total

Review 1.  Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa.

Authors:  Robert A Bonomo; Dora Szabo
Journal:  Clin Infect Dis       Date:  2006-09-01       Impact factor: 9.079

2.  In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012.

Authors:  A Walkty; J A Karlowsky; H Adam; M Baxter; P Lagacé-Wiens; D J Hoban; G G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2013-08-12       Impact factor: 5.191

3.  Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii.

Authors:  A S Levin; A A Barone; J Penço; M V Santos; I S Marinho; E A Arruda; E I Manrique; S F Costa
Journal:  Clin Infect Dis       Date:  1999-05       Impact factor: 9.079

4.  Ceftolozane/Tazobactam Therapy of Respiratory Infections due to Multidrug-Resistant Pseudomonas aeruginosa.

Authors:  Michael S Gelfand; Kerry O Cleveland
Journal:  Clin Infect Dis       Date:  2015-05-28       Impact factor: 9.079

5.  The Effectiveness and Safety of High-Dose Colistin: Prospective Cohort Study.

Authors:  Yael Dishon Benattar; Muna Omar; Oren Zusman; Dafna Yahav; Yael Zak-Doron; Sergey Altunin; Michal Elbaz; Vered Daitch; Michal Granot; Leonard Leibovici; Mical Paul
Journal:  Clin Infect Dis       Date:  2016-10-06       Impact factor: 9.079

6.  Susceptibility Profile of Ceftolozane/Tazobactam and Other Parenteral Antimicrobials Against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa From US Hospitals.

Authors:  Christina A Sutherland; David P Nicolau
Journal:  Clin Ther       Date:  2015-06-15       Impact factor: 3.393

7.  Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates.

Authors:  Deanna J Buehrle; Ryan K Shields; Liang Chen; Binghua Hao; Ellen G Press; Ammar Alkrouk; Brian A Potoski; Barry N Kreiswirth; Cornelius J Clancy; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

Review 8.  Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations.

Authors:  David van Duin; Robert A Bonomo
Journal:  Clin Infect Dis       Date:  2016-04-20       Impact factor: 9.079

9.  Influence of Colistin Dose on Global Cure in Patients with Bacteremia Due to Carbapenem-Resistant Gram-Negative Bacilli.

Authors:  Gabrielle A Gibson; Seth R Bauer; Elizabeth A Neuner; Stephanie N Bass; Simon W Lam
Journal:  Antimicrob Agents Chemother       Date:  2015-11-02       Impact factor: 5.191

10.  Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa.

Authors:  Peter K Linden; Shimon Kusne; Kim Coley; Paulo Fontes; David J Kramer; David Paterson
Journal:  Clin Infect Dis       Date:  2003-10-29       Impact factor: 9.079
View more
  41 in total

Review 1.  Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: a perilous journey toward 'molecularly targeted' therapy.

Authors:  Nadim G El Chakhtoura; Elie Saade; Alina Iovleva; Mohamad Yasmin; Brigid Wilson; Federico Perez; Robert A Bonomo
Journal:  Expert Rev Anti Infect Ther       Date:  2018-01-16       Impact factor: 5.091

2.  Ceftolozane/tazobactam for the treatment of MDR Pseudomonas aeruginosa left ventricular assist device infection as a bridge to heart transplant.

Authors:  Maddalena Peghin; Massimo Maiani; Nadia Castaldo; Filippo Givone; Elda Righi; Andrea Lechiancole; Assunta Sartor; Federico Pea; Ugolino Livi; Matteo Bassetti
Journal:  Infection       Date:  2017-10-31       Impact factor: 3.553

Review 3.  [New β‑lactam antibiotics and β‑lactamase inhibitors against multidrug-resistant Gram-negative bacteria].

Authors:  Alexander Mischnik; Christoph Lübbert; Nico T Mutters
Journal:  Internist (Berl)       Date:  2018-12       Impact factor: 0.743

4.  The clinical significance of pneumonia in patients with respiratory specimens harbouring multidrug-resistant Pseudomonas aeruginosa: a 5-year retrospective study following 5667 patients in four general ICUs.

Authors:  B Borgatta; S Gattarello; C A Mazo; A T Imbiscuso; M N Larrosa; M Lujàn; J Rello
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-06-17       Impact factor: 3.267

Review 5.  The Continued Value of Disk Diffusion for Assessing Antimicrobial Susceptibility in Clinical Laboratories: Report from the Clinical and Laboratory Standards Institute Methods Development and Standardization Working Group.

Authors:  Romney M Humphries; Susan Kircher; Andrea Ferrell; Kevin M Krause; Rianna Malherbe; Andre Hsiung; C A Burnham
Journal:  J Clin Microbiol       Date:  2018-07-26       Impact factor: 5.948

6.  Ceftolozane/tazobactam for the treatment of XDR Pseudomonas aeruginosa infections.

Authors:  Laura Escolà-Vergé; Carles Pigrau; Ibai Los-Arcos; Ángel Arévalo; Belen Viñado; David Campany; Nieves Larrosa; Xavier Nuvials; Ricard Ferrer; Oscar Len; Benito Almirante
Journal:  Infection       Date:  2018-03-28       Impact factor: 3.553

7.  Real-World Experience with Ceftolozane-Tazobactam for Multidrug-Resistant Gram-Negative Bacterial Infections.

Authors:  Sarah C J Jorgensen; Trang D Trinh; Evan J Zasowski; Abdalhamid M Lagnf; Samuel P Simon; Sahil Bhatia; Sarah M Melvin; Molly E Steed; Natalie A Finch; Taylor Morrisette; Sandy J Estrada; Joshua R Rosenberg; Susan L Davis; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

8.  A 2.5-years within-patient evolution of a Pseudomonas aeruginosa with in vivo acquisition of ceftolozane-tazobactam and ceftazidime-avibactam resistance upon treatment.

Authors:  Thibaud Boulant; Agnès B Jousset; Rémy A Bonnin; Aurélie Barrail-Tran; Adrien Borgel; Saoussen Oueslati; Thierry Naas; Laurent Dortet
Journal:  Antimicrob Agents Chemother       Date:  2019-10-21       Impact factor: 5.191

9.  Ceftolozane-tazobactam therapy for multidrug-resistant Pseudomonas aeruginosa infections in patients with hematologic malignancies and hematopoietic-cell transplant recipients.

Authors:  Morgan Hakki; James S Lewis
Journal:  Infection       Date:  2018-02-19       Impact factor: 3.553

10.  Performance of Ceftolozane-Tazobactam Etest, MIC Test Strips, and Disk Diffusion Compared to Reference Broth Microdilution for β-Lactam-Resistant Pseudomonas aeruginosa Isolates.

Authors:  Romney M Humphries; Janet A Hindler; Paul Magnano; Annie Wong-Beringer; Robert Tibbetts; Shelley A Miller
Journal:  J Clin Microbiol       Date:  2018-02-22       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.